Acute Encephalopathy during First Pembrolizumab Infusion Followed by Delayed Multisystem Immune Toxicity in Recurrent Vaginal Cancer: A Case Report
Case Reports in Oncology · 2026-08-28 · 19 (1) · 1493-1500
DOI: 10.1159/cro/abzag026 ↗Abstract
Introduction: Primary vaginal cancer is a rare malignancy, and treatment strategies are often extrapolated from cervical cancer due to limited prospective data. Immune checkpoint inhibitors (ICIs), including pembrolizumab, have demonstrated efficacy in gynecologic cancers but are associated with immune-related adverse events (irAEs), which can involve multiple organ systems. Neurologic irAEs are uncommon but may be severe and diagnostically challenging. Case Presentation: We present a 67-year-old woman with recurrent HPV-associated squamous cell carcinoma of the vagina who developed acute encephalopathy after receiving bevacizumab and paclitaxel and within minutes of initiating pembrolizumab during her first treatment cycle. Symptoms included confusion, hallucinations, and agitation. Extensive evaluation did not identify an infectious, metabolic, structural, epileptic, malignant, or antibody-mediated cause. She required intensive care support, and her mental status improved with supportive management. Although the temporal association raised concern for an immune-mediated neurologic event, the immediate onset, exposure to multiple agents, absence of objective inflammatory findings, and improvement without corticosteroids limited causal attribution. Four weeks later, she developed suspected multisystem irAEs characterized by myositis, transaminitis, and worsening thyroid dysfunction, necessitating high-dose corticosteroids and multidisciplinary management. Pembrolizumab was discontinued, and she was transitioned to single-agent chemotherapy. Conclusion: This case highlights the diagnostic complexity of acute neurologic symptoms arising during ICI-containing combination therapy, followed by delayed multisystem immune-related toxicity. Clinicians should recognize that acute neurologic symptoms may arise during the first immunotherapy treatment and require prompt evaluation for immune-mediated toxicity as well as infusion-related, medication-associated, vascular, infectious, metabolic, and malignant causes. Early recognition and multidisciplinary collaboration are critical to reducing morbidity. Given the limited data on immunotherapy in vaginal cancer, continued reporting of such cases is essential to inform safety, guide management, and improve patient selection in this rare disease.
EUVIMED